Clinical Trial: Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a

Brief Summary: This study will test an investigational drug, theophylline, in children with pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the Vanderbilt Clinical Research Center.

Detailed Summary: Study measures will be done at baseline and during a 24h infusion of IV theophylline. Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity. Measures include laboratory values, response to PTH infusion and resting energy expenditure.
Sponsor: Vanderbilt University Medical Center

Current Primary Outcome: Urine cAMP [ Time Frame: 1 day ]

Change in urine cAMP (after parathyroid hormone stimulation) before and during treatment with theophylline


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Resting Energy Expenditure (REE) [ Time Frame: 1 day ]
    Change in REE before and during treatment with theophylline
  • Apnea Hypopnea Index (AHI) [ Time Frame: 1 day ]
    Change in AHI before and during treatment with theophylline


Original Secondary Outcome: Same as current

Information By: Vanderbilt University Medical Center

Dates:
Date Received: May 20, 2015
Date Started: June 2015
Date Completion:
Last Updated: April 19, 2017
Last Verified: April 2017